Using an IGFIR-KO ER+ BC model, selectively expressing IRA or IRB we investigated the role of glucose levels on ER and IRs interplay on drug response using the selective estrogen receptor modulator (SERM) TAM (24, 25). The gene discussed is IGF1R; the disease is breast cancer.